Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;247(15):1330-1334.
doi: 10.1177/15353702221108914. Epub 2022 Jul 27.

COVID-19 and diabetes: What do we know so far?

Prakash Gangadaran  1   2 , Himabindu Padinjarathil  3   4 , Shri Hari Subhashri Rajendran  5 , Manasi P Jogalekar  6 , Chae Moon Hong  2 , Baladhandapani Aruchamy  3   4 , Uma Maheswari Rajendran  7 , Sridharan Gurunagarajan  8 , Anand Krishnan  9 , Prasanna Ramani  3   4 , Kavimani Subramanian  5
Affiliations
Review

COVID-19 and diabetes: What do we know so far?

Prakash Gangadaran et al. Exp Biol Med (Maywood). 2022 Aug.

Abstract

Coronavirus disease 2019 (COVID-19) management has been challenging for patients with comorbidities. Patients with diabetes and COVID-19, in particular, have shown severe symptoms and rapid progression of the disease. They also have a high mortality rate compared to the non-diabetic population. The high mortality rate is caused in people with diabetes who are in a pro-inflammatory condition; this could worsen COVID-19. In addition, people with diabetes have circulatory issues and COVID-19 infection can lead to further clotting problems. It is critical to understand the mechanisms underlying the adverse clinical outcomes in patients with diabetes and COVID-19. This review discusses various disease conditions contributing to poor prognosis in diabetic COVID-19 patients such as hyperglycemia, insulin resistance, impaired pancreatic function, and production of advanced glycation end products.

Keywords: COVID-19; SARS-CoV-2; diabetics; hyperglycemia; insulin resistance.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
COVID-19 and diabetics. Source: Created with BioRender.com. (A color version of this figure is available in the online journal.)
See this image and copyright information in PMC

References

    1. Jogalekar MP, Veerabathini A, Gangadaran P. Novel 2019 coronavirus: genome structure, clinical trials, and outstanding questions. Exp Biol Med (Maywood) 2020;245:964–9 - PMC - PubMed
    1. Jogalekar MP, Veerabathini A, Gangadaran P. SARS-CoV-2 variants: a double-edged sword. Exp Biol Med (Maywood) 2021;246:1721–6 - PMC - PubMed
    1. Manivannan M, Jogalekar MP, Kavitha MS, Maran BAV, Gangadaran P. A mini-review on the effects of COVID-19 on younger individuals. Exp Biol Med (Maywood) 2021;246:293–7 - PMC - PubMed
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–62 - PMC - PubMed
    1. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020;109:531–8 - PMC - PubMed